Cyclacel Pharmaceuticals Inc’s recently made public that its 10% Owner Lazar David E. unloaded Company’s shares for reported $83430.0 on Jul 30 ’25. In the deal valued at $12.36 per share,6,750 shares were sold. As a result of this transaction, Lazar David E. now holds 155,838 shares worth roughly $1.28 million.
Then, Lazar David E. sold 194,628,820 shares, generating $5,507,996 in total proceeds. Upon selling the shares at $0.03, the Interim CEO now owns 0 shares.
Ladenburg Thalmann began covering CYCC with “Buy” recommendation on September 07, 2018. H.C. Wainwright started covering the stock on October 16, 2015. It rated CYCC as “a Buy”.
Price Performance Review of CYCC
On Friday, Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] saw its stock jump 5.31% to $8.23. Over the last five days, the stock has gained 3.07%. Cyclacel Pharmaceuticals Inc shares have fallen nearly -97.04% since the year began. Nevertheless, the stocks have fallen -90.87% over the past one year. While a 52-week high of $597.60 was reached on 01/03/25, a 52-week low of $3.08 was recorded on 07/07/25.
Levels Of Support And Resistance For CYCC Stock
The 24-hour chart illustrates a support level at 7.71, which if violated will result in even more drops to 7.18. On the upside, there is a resistance level at 8.79. A further resistance level may holdings at 9.34.
How much short interest is there in Cyclacel Pharmaceuticals Inc?
A steep rise in short interest was recorded in Cyclacel Pharmaceuticals Inc stocks on 2025-08-15, dropping by 58858.0 shares to a total of 64256.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 0.12 million shares. There was a decline of -91.6%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 04, 2010 when Roth Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
